Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Substance use and survival after treatment for chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS).

Chang G, Meadows ME, Jones JA, Antin JH, Orav EJ.

Am J Drug Alcohol Abuse. 2010 Jan;36(1):1-6. doi: 10.3109/00952990903490758.

2.

Prognostic significance of monocytosis in patients with myeloproliferative disorders.

Beran M, Shen Y, Onida F, Wen S, Kantarjian H, Estey E.

Leuk Lymphoma. 2006 Mar;47(3):417-23.

PMID:
16396764
3.

Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.

Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N, Uchida N, Nakamae H, Ichinohe T, Morishima Y, Suzuki R, Yamaguchi T, Fukuda T.

Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26.

4.

Predictors of neuropsychological change in patients with chronic myelogenous leukemia and myelodysplastic syndrome.

Meadows ME, Chang G, Jones JA, Antin JR, Orav EJ.

Arch Clin Neuropsychol. 2013 Jun;28(4):363-74. doi: 10.1093/arclin/acs141. Epub 2013 Feb 7.

5.

Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation.

Koh H, Nakamae H, Hagihara K, Nakane T, Manabe M, Hayashi Y, Nishimoto M, Umemoto Y, Nakamae M, Hirose A, Inoue E, Inoue A, Yoshida M, Bingo M, Okamura H, Aimoto R, Aimoto M, Terada Y, Koh KR, Yamane T, Ohsawa M, Hino M.

J Exp Clin Cancer Res. 2011 Apr 10;30:36. doi: 10.1186/1756-9966-30-36.

6.
7.

Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.

Onida F, Ball G, Kantarjian HM, Smith TL, Glassman A, Albitar M, Scappini B, Rios MB, Keating MJ, Beran M.

Cancer. 2002 Oct 15;95(8):1673-84.

8.

Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.

Shiobara S, Nakao S, Ueda M, Yamazaki H, Takahashi S, Asano S, Yabe H, Kato S, Imoto S, Maruta A, Yoshida T, Gondo H, Morishima Y, Kodera Y.

Bone Marrow Transplant. 2000 Oct;26(7):769-74.

9.

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.

Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):401-10. doi: 10.1016/j.clml.2014.03.001. Epub 2014 May 6.

10.

Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults.

Zandberg DP, Huang TY, Ke X, Baer MR, Gore SD, Smith SW, Davidoff AJ.

Haematologica. 2013 Apr;98(4):584-90. doi: 10.3324/haematol.2012.062547. Epub 2012 Nov 9.

11.

Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.

Chan GC, Wang WC, Raimondi SC, Behm FG, Krance RA, Chen G, Freiberg A, Ingram L, Butler D, Head DR.

Leukemia. 1997 Feb;11(2):206-11. Review.

PMID:
9009082
12.

Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.

Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O'Reilly RJ, Horowitz MM, Dupont B.

Blood. 2005 Jun 15;105(12):4878-84. Epub 2005 Feb 24.

13.

HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation.

Woolfrey A, Klein JP, Haagenson M, Spellman S, Petersdorf E, Oudshoorn M, Gajewski J, Hale GA, Horan J, Battiwalla M, Marino SR, Setterholm M, Ringden O, Hurley C, Flomenberg N, Anasetti C, Fernandez-Vina M, Lee SJ.

Biol Blood Marrow Transplant. 2011 Jun;17(6):885-92. doi: 10.1016/j.bbmt.2010.09.012. Epub 2010 Sep 24.

14.

Extramedullary myeloid cell tumors in myelodysplastic-syndromes: not a true indication of impending acute myeloid leukemia.

Byrd JC, Edenfield WJ, Dow NS, Aylesworth C, Dawson N.

Leuk Lymphoma. 1996 Mar;21(1-2):153-9. Review.

PMID:
8907283
15.

[Prognostic factors and survival in chronic myeloproliferative disorders].

Kvasnicka HM, Thiele J, Schmitt-Graeff A, Schaefer HE.

Pathologe. 2000 Jan;21(1):63-72. German.

PMID:
10663670
16.

Acute lymphoid leukemias following either a previous chronic myelogenous leukemia or myelodysplastic syndrome: phenotypic and genomic differences.

Hernández JM, Sánchez I, González M, Orfao A, González-Sarmiento R, San Miguel JF.

Am J Hematol. 1993 Aug;43(4):256-8.

PMID:
8396849
17.

Myelodysplastic syndrome (MDS)-associated cytogenetic abnormalities in pediatric chronic myelogenous leukemia.

Kumar KR, Koduru P, Timmons C, Monaghan S, Cavalier M, Luu HS.

Pediatr Blood Cancer. 2013 Nov;60(11):E146-8. doi: 10.1002/pbc.24645. Epub 2013 Jul 18.

PMID:
23868765
18.

Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome.

Potter VT, Krishnamurthy P, Barber LD, Lim Z, Kenyon M, Ireland RM, de Lavallade H, Dhouri A, Marsh JC, Marcus R, Devereux S, Ho A, Pagliuca A, Mufti GJ.

Biol Blood Marrow Transplant. 2014 Jan;20(1):111-7. doi: 10.1016/j.bbmt.2013.10.021. Epub 2013 Nov 8.

19.

Chronic lymphocytic leukemia associated with myelodysplastic syndrome and/or chronic myeloid leukemia: evidence for independent clonal chromosomal evolution.

Mossafa H, Fourcade C, Pulic M, Jary L, Cheze S, Szpiro-Tapia S, Troussard X.

Leuk Lymphoma. 2001 Apr;41(3-4):337-41.

PMID:
11378546
20.

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.

Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW.

J Clin Oncol. 2011 May 20;29(15):1987-96. doi: 10.1200/JCO.2010.30.9245. Epub 2011 Apr 11.

PMID:
21483003

Supplemental Content

Support Center